RE:Winning the Battle against Septic Shock Paradigm's last target price ( April) was based on a 120,000 targeted patient population and 35% market penetration
Spectral's latest EBITDA analysis is based on 140,000 but provides no SP target like Paradigm .
140k/120k = 1.16.
If paradigm used the same number of patients in their assumptions, their target would presumably be 16% higher or over $2.
Paradigm also says that they consider their analysis and target to be based on very conservative assumptions.
Spectral also seems to be using a very conservative " per column" projected prices. Of course results that greatly exceeded expected results in terms of mortality benefit and other outcomes ( think reduced hospital costs from reduced ventilator use, etc) should command a higher price - one would think.
MM